Holen Sie sich die Stockscreener-App
1.38
2.22%
0.03
Schlusskurs vom Vortag:
$1.35
Offen:
$1.345
24-Stunden-Volumen:
303.54K
Relative Volume:
0.42
Marktkapitalisierung:
$99.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.304
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+2.99%
1M Leistung:
-0.72%
6M Leistung:
+2.22%
1J Leistung:
-57.14%
1-Tages-Spanne:
$1.34
$1.39
1-Wochen-Bereich:
$1.33
$1.46
52-Wochen-Spanne:
$1.01
$3.33
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.38 | 97.54M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings season2025 Market Sentiment & AI Forecast for Swing Trade Picks - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell - GlobeNewswire Inc.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. stock a safe haven asset2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
New Highs: Will Zentalis Pharmaceuticals Inc stock outperform growth indexesMarket Risk Report & Risk Controlled Stock Pick Alerts - BỘ NỘI VỤ
Is Zentalis Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Summary & Free Daily Entry Point Trade Alerts - Newser
Are Bears Losing Grip on Artson LimitedMarket Capitalization Trends & Reduce Losses With Smart Exit Strategies - earlytimes.in
Is Zentalis Pharmaceuticals Inc. stock trading near support levels2025 Pullback Review & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockBuy Signal & Momentum Based Trading Ideas - newser.com
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - MarketBeat
Can Zentalis Pharmaceuticals Inc. stock reach $100 price target2025 Key Highlights & Weekly High Return Stock Opportunities - newser.com
FY2025 Earnings Estimate for ZNTL Issued By Leerink Partnrs - Defense World
What is HC Wainwright’s Estimate for ZNTL FY2025 Earnings? - Defense World
Wedbush Expects Higher Earnings for Zentalis Pharmaceuticals - MarketBeat
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Myers Scott Dunseth | Director |
Apr 30 '25 |
Buy |
1.40 |
21,000 |
29,373 |
281,192 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.36%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):